The Beijing Pharmaceutical Enterprise Financing Sharing Conference was grandly held at Haibu Pharmaceutical.

　　On May 10, 2019, the Beijing Pharmaceutical Enterprise Financing Sharing Conference was grandly held at Haibu Pharmaceutical. It brought together 33 pharmaceutical companies in Beijing, including Baiaosaitu, Baihui Weikang (Remebot), China Resources Pharmaceutical, Yangtze River Pharmaceutical, and 27 investment institutions such as Tongchuang Weiye, Puhua Capital, Junlian, and Mifang. Everyone gathered to discuss financing for Beijing's pharmaceutical enterprises.

　　The conference was jointly organized by Tongchuang Weiye, Puhua Capital, Haibu Pharmaceutical, Zhenzhen Capital, and Qiyuan Capital. There were seven sections: "Financial Norms and Planning Before the Next Round of Financing," "Legal Issues at Different Stages of Enterprise Development," "Observation of Haibu Pharmaceutical Laboratory," "Discussion on Management of Pharmaceutical Enterprises," "Making Financing More Efficient," "Key Points on Financing that CEOs Need to Know," and "Investment Analysis by First-Line Medical Investment Institutions." Guest speakers shared practical experiences in the financing process from perspectives of corporate finance, legal affairs, operational management, and investment financing. The meeting was hosted by Li Yang from Puhua Capital.

　　The theme shared by Chen Jianqiang, Director of Post-Investment at Puhua Capital, was "Financial Norms and Planning Before the Next Round of Financing." When establishing financial norms, many details need to be considered such as financing entities, related party transactions, personnel costs (salaries and social security), potential liabilities; financial planning should consider business closure loops, shareholding platforms, equity payments, listing channels etc. Chen Jianqiang summarized ten major issues that enterprises should pay significant attention to including equity defects, unrelated business investments to the main business sector, compliance issues with bills etc., stating that if these are resolved before institutional due diligence entry then the success rate of financing will be significantly higher. He provided numerous examples to support his points; for instance when discussing fund occupation he mentioned that occupied funds should also be calculated using a market reference value (such as bank loan interest rates during the same period) for reasonable cost assessment. The best solution is for shareholders to take personal loans from banks and then lend them to the company.

　　The discussion on corporate financial management was hosted by Chen Jianqiang. He answered questions regarding financing on the New Third Board. He believes that a major issue with the New Third Board is that user thresholds are too high and that financing difficulties arise from a lack of transparency in information mechanisms.

　　Yuan Yichao, founder of Wanshang Tianqin Law Firm shared on 'Legal Issues at Different Stages of Enterprise Development.' First: Shareholder contributions and transfers - discussed aspects such as limited liability penetration issues with intellectual property contributions; tax issues related to capital reserve increases in share capital; tax principles for equity transfers; differences between joint-stock companies and limited liability companies; Second: Equity structure and incentive - emphasized the importance of reasonably building enterprise equity structure and having clear ideas about equity incentives for enterprise development; Third: Basic requirements for capital markets - explained enterprise development dilemmas combined with compliance requirements based on different stages; Fourth: Ways for enterprises to improve performance - mergers & acquisitions vs incubation models based on years of legal service experience providing effective methods for performance enhancement; Fifth: Intellectual property protection - given that pharmaceutical enterprises are knowledge-intensive industries provided comprehensive suggestions on intellectual property protection from external risks and internal management perspectives combined with detailed case studies.

　　The discussion on corporate legal affairs was hosted by Yuan Yichao. A company asked about how to effectively bind responsibilities between an invested enterprise whose actual controller is a foreign national holding shares through another person while investors require binding responsibilities between the enterprise and its actual controller. Lawyer Yuan believes that the core issue lies in how investors can limit obligations of actual controllers: first can include actual controllers as one party in agreements; second can list these actual controllers among key personnel in agreements adding joint obligations.

　　Zhang Fang, Vice President of Zhenzhen Capital shared her theme 'Making Financing More Efficient.' She summarized years of experience in investment financing into methodologies for making financing more efficient. Zhang Fang systematically discussed various aspects involved in corporate financing including BP writing, investor selection techniques communication skills valuation risk control efficiency improvement etc., highlighting key points entrepreneurs need to pay attention to during their financing processes while also providing techniques they should master which helped attendees gain clear understanding regarding key issues in corporate financing; additionally she illustrated PR's important role during corporate financing processes using a well-known medical imaging company's successful fundraising experience in 2018 as an example detailing flexible applications like media interviews professional award selections WeChat platform exposure which successfully assisted companies in obtaining two rounds of funding under poor capital conditions helping entrepreneurs truly recognize PR's significance pointing out correct directions for future promotions.

　　Jin Xiao founder of Qiyuan Capital shared her theme 'Key Points CEOs Need to Know About Financing.' She mentioned that choosing timing for financing must comprehensively consider remaining funds available funding purposes amounts current capital market conditions milestones industry/competitor situations etc., while once initiated it’s crucial to seize market window periods avoiding prolonged timelines she also provided deep insights into different types' funding strategies for companies throughout 2019; For example projects currently trending should be open-minded about releasing equity when raising funds ensuring they secure enough money covering future two years since no one can predict how long this trend will last. Additionally she combined her years-long experience giving emphasis on common mistakes enterprises make when communicating with institutions across different stages like initial roadshows Pre DD TS etc., along with materials they could provide investors.

　　Xi Yanbin Vice President at Tongchuang Weiye shared his theme 'Investment Analysis by First-Line Medical Investment Institutions.' He comprehensively analyzed investment situations within primary medical markets across provinces cities segmented tracks based upon representative institutions providing focused interpretations which received frequent agreement from attendees due his insightful analysis.

　　A roundtable forum discussing corporate operational management was hosted by Liu Changru Chairman at Haibu Pharmaceutical featuring discussions among Wang Wenfeng CEO at China Resources Pharmaceuticals (Beijing Medical Research Center), Ding Hongxia CEO at Yaodu and Wang Chengzhen Deputy General Manager at Aotai Kang. While sharing their experiences managing enterprises they emphasized not only focusing efforts towards process management ensuring organized operations but also valuing strengthening information technology construction improving overall management efficiency according Liu Changru’s words after years entrepreneurship she summarized two phrases: 'First is finding every possible way attracting top talents into teams; Second is striving through managerial methods reducing organizational dependency upon these individuals.'

　　During breaks Liu Changru led representatives visiting Haibu Pharmaceutical's over 4000 square meter laboratory where attendees expressed affirmation towards its meticulous onsite management along with foresight implementing R&D information technology construction actively engaging staff members onsite discussions. Liu Changru introduced currently nearly a team comprising around200 researchers providing pharmaceutical CRO services high-end raw materials intermediates R&D associated registrations custom productions both domestically internationally while future plans include increasing chemical drug formulation product developments production sales efforts alongside detailing how Haibu meticulously cultivates R&D management details enhancing information technology construction achieving leapfrog developments summarizing finally stating 'Every researcher within Haibu must hold reverence towards life maintaining scientific rigor truth-seeking pragmatic spirit striving perfection throughout each R&D phase.'

　　The conference was fully attended, with entrepreneurs and investors gathering together and engaging in lively discussions. Whether in the break room or the sofa area, there were always two or three people sitting together to exchange ideas. "This meeting deepened my understanding of controlling the financing process and helped me pay more attention to finance, legal affairs, and PR aspects. Especially since the speakers provided numerous case studies, it greatly aided my own thinking; it was full of valuable insights," said Zhang Shengming, CEO of Jianyi Bao, after the event. Yan Jingjing, a partner at Probe Capital, remarked afterward: "In this exchange, we found that everyone had different takeaways. We will hold more similar events in the future; not only can everyone learn and recharge, but when we gather together, resources can collide and perhaps spark something exciting. This is very thrilling."